Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

NCT04070781 | Terminated Phase 1 DMC FDA Drug

• 1 other identifier: AAAR8757
• Study Type: interventional
• Target: 1
• Locations: 1 country
• Sites: 2

Brief Summary

The study's primary objective is designed to assess the safety and tolerability, and determine the maximum tolerated dose (MTD) of both itacitinib and tocilizumab when given in combination to patients with steroid-refractory acute graft versus host disease (SR-aGVHD). The study's secondary objectives are to:

• Estimate the day 28 response rate (ORR) \[complete response (CR), very good partial response (VGPR), and partial response (PR)\] of the combination of itacitinib and tocilizumab for the treatment of SR-aGVHD
• Estimate the time to response and duration of response
• Estimate the incidence of primary disease relapse while on study treatment
• Estimate the incidence of infections including viral reactivation, bacterial infections and fungal infections while on study treatment
• Estimate the progression-free survival (PFS), overall survival (OS), non-relapse mortality, GVHD-related mortality of study subjects
• Estimate the proportion of patients who successfully discontinue steroids by 6 months and 12 months after therapy initiation

Conditions

Steroid Refractory GVHD; Graft Vs Host Disease

Keywords

Steroid Refractory GVHD

Outcome Measures

Primary Outcomes (2)

• MTD of Tocilizumab IV infusion when given with Itacitinib

  Maximum Tolerated Dose (MTD) is the highest dose of a drug or treatment that does not cause unacceptable side effects.

  28 - 35 days after the End of Treatment (EOT) or the date of the last dose of the study drug

• Access Safety and Tolerability

  The safety and tolerability of study treatment is measured by the frequency and severity of adverse events and serious adverse events.

  End of Cycle 1 (approximately 28 days)

Secondary Outcomes (8)

• Objective Response Rate (ORR)

  End of Cycle 1 (approximately 28 days)

• Time to Response

  Up to 36 months

• Duration of Response

  Up to 36 months

• Incidence of Disease Relapse

  Up to 36 months

• Incidence of Infections

  Up to 36 months

Study Arms (2)

Itacitinib + Tocilizumab

EXPERIMENTAL

A dose de-escalation design will be used to identify the MTD of both itacitinib and tocilizumab when given in combination. The following two levels will be tested with at least 6 patients per dose: * Dose level 1: Itacitinib 200 mg daily + tocilizumab 8mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Starting dose level * Dose level -1: Itacitinib 200 mg daily + tocilizumab 4mg/kg on cycle 1, day 1 (can repeat cycle 2 day 1 if Partial Response (PR) - Dose De-escalation level Itacitinib will be given daily in 28-day long cycles, tocilizumab will be given every 4 weeks in 28-day cycles.

Drug: Itacitinib; Drug: Tocilizumab

Dose Expansion

EXPERIMENTAL

Once the MTD is determined, an additional 10 patients as an expansion cohort to further define the safety profile of the combination and estimate its response rate.

Drug: Itacitinib; Drug: Tocilizumab

Interventions

Itacitinib DRUG

Itacitinib is a novel, potent, and selective inhibitor of the Janus Kinase (JAK) family of protein tyrosine kinases (TYKs) with selectivity for Janus Kinase 1 (JAK1). Itacitinib is an investigational product. Itacitinib 200 mg daily in 28-day long cycles

Also known as: Itacitinib adipate

Dose Expansion; Itacitinib + Tocilizumab

Tocilizumab DRUG

Tocilizumab is a biologic medication currently approved to treat adults with moderately to severely active rheumatoid arthritis (RA), adults with giant cell arteritis (GCA), and children ages two and above with Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA). Tocilizumab blocks the inflammatory protein interleukin 6 (IL-6). This improves joint pain and swelling from arthritis and other symptoms caused by inflammation. Tocilizumab 4 or 8mg/kg cycle 1 day 1 every 4 weeks in 28-day cycles

Also known as: Actemra

Dose Expansion; Itacitinib + Tocilizumab

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult men and women who are at least 18 years of age
• Recipients of their first allogeneic hematopoietic stem cell transplant from any donor source (including bone marrow, mobilized peripheral blood, cord blood) and human leukocyte antigen (HLA)-match (includes matched related, matched unrelated, mismatched unrelated, and haploidentical)
• Recipients of allogeneic stem cell transplant after any conditioning regimen intensity and those who have received any GVHD prophylaxis regimen, unless it included tocilizumab and/or itacitinib
• Steroid refractory acute GVHD (SR-aGVHD) that has been clinically diagnosed as per the MAGIC criteria and/or pathologically confirmed. Biopsies should be attempted whenever possible according to the investigator's discretion but it is not required as long as alternative diagnoses such as infection or medication side effects have been adequately ruled out. SR-aGVHD is defined as acute GVHD that has failed to exhibit a response after treatment for at least 7 days with a corticosteroid dose of 2 mg/kg of methylprednisolone or prednisone equivalent. SR-aGVHD is also defined as GVHD that flares when steroids are tapered prohibiting further taper.
• Adequate renal function determined by creatinine clearance ≥ 40 mL/min measured or calculated by Cockcroft-Gault equation.
• Absence of history of irreversible liver disease such as cirrhosis or veno-occlusive disease (VOD) that has not responded to therapy
• Total bilirubin and/or transaminases (AST and/or ALT) that are ≤2.5 above institutional upper limit of normal that is not attributable to acute GVHD by biopsy
• Non-pregnant females or men and women willing to avoid pregnancy or fathering a child as evidenced by negative pregnancy test (females), non-childbearing potential (history of hysterectomy, oophorectomy, amenorrhea for 12 months) or agree to use barrier or chemical contraception for the duration of the study.
• Ability to swallow oral medication
• Able to give consent and comply with study visits and procedures

You may not qualify if:

• Primary disease not in complete remission, requiring active treatment, or having required treatment for relapsed disease
• Uncontrolled bacterial, viral, or fungal infections which is evidenced by hemodynamic instability, new radiological findings, new signs or symptoms, or persistently positive blood cultures as determined by the investigator.
• History of viral infection with HIV
• History of infection or exposure to hepatitis B or C with a risk of infection reactivation
• History of active or latent tuberculosis infection that has not been adequately treated
• Use of any JAK inhibitor or IL-6 antagonists for therapy or prophylaxis of acute GVHD. Continuation of calcineurin inhibitors intended for GVHD prophylaxis is allowed. Resumption of therapeutic dosing of calcineurin inhibitors that is being tapered is also allowed.
• Severe organ dysfunction unrelated to GVHD that includes cholestatic disorders or unresolved VOD (defined as ongoing organ dysfunction and bilirubin elevation unrelated to GVHD \> 2.5 the institutional upper limit of normal), clinically significant or uncontrolled cardiac disease (including unstable angina, acute myocardial infarction within 6 months of enrollment, New York Heart Association, Class III or IV congestive heart failure, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia that requires therapy) or clinically significant respiratory disease that requires mechanical ventilation support or 50% or greater supplemental oxygen..
• Receipt of live attenuated vaccine or the need for such a vaccine during the duration of the study
• Treatment with any other investigational agent within 7 days of enrollment (or 5 half-lives, whichever is greater)
• Treatment with any JAK inhibitor or IL-6 antagonist after stem cell transplant. Treatment with a JAK inhibitor before transplant is allowed. Treatment with IL-6 antagonist before transplant is allowed only if last dose was at least 4 weeks prior to transplant.
• Known allergies or sensitivities to itacitinib or tocilizumab
• Pregnant, breast-feeding, or unwilling or unable to avoid pregnancy or fathering a child. Pregnant women are excluded from this study as animal studies have shown that tocilizumab crosses the placenta and can interfere with fetal development in animal studies. Furthermore, itacitinib has been associated with embryo-fetal toxicity in animal studies

Sponsors & Collaborators

• Columbia University: lead
• Incyte Corporation: collaborator

Study Sites (2)

Columbia University Irving Medical Center

New York, New York, 10032, United States

Location

Weill Cornell Medical College - New York Presbyterian Hospital

New York, New York, 10065, United States

Location

Related Links

• Columbia University Medical Center

MeSH Terms

Conditions

Graft vs Host Disease

Interventions

itacitinib; tocilizumab

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

• Markus Mapara, MD

  Columbia University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2019
• First Posted: August 28, 2019
• Study Start: January 20, 2020
• Primary Completion: December 13, 2021
• Study Completion: December 13, 2021
• Last Updated: June 4, 2024

Record last verified: 2024-05

Locations

US (2)